View ValuationVectus Biosystems 将来の成長Future 基準チェック /06現在、 Vectus Biosystemsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長34.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 27Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million.Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million. Security Name: Odinary Shares Security Type: Common Stock Securities Offered: 7,910,000 Price\Range: AUD 0.1 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • May 22Vectus Biosystems Limited has filed a Follow-on Equity Offering.Vectus Biosystems Limited has filed a Follow-on Equity Offering. Security Name: Odinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • Oct 09Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.033 loss per share (vs AU$0.044 loss in FY 2024)Full year 2025 results: AU$0.033 loss per share (improved from AU$0.044 loss in FY 2024). Revenue: AU$478.2k (down 58% from FY 2024). Net loss: AU$1.78m (loss narrowed 24% from FY 2024).Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 20Vectus Biosystems Limited Appoints Linda Ann Walters as Non-Executive Director of the BoardVectus Biosystems Limited announced the appointment of Linda Ann Walters as a non-executive director of the board of the company, effective from 20 December 2024. Linda Walters has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. Linda has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization programme. Her expertise spans the fields of human resources, finance, information technology and the commercialization of IP. Linda has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus' operational and commercial capabilities.お知らせ • Oct 08Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024.Reported Earnings • Oct 05Full year 2024 earnings released: AU$0.044 loss per share (vs AU$0.072 loss in FY 2023)Full year 2024 results: AU$0.044 loss per share (improved from AU$0.072 loss in FY 2023). Revenue: AU$1.14m (down 16% from FY 2023). Net loss: AU$2.34m (loss narrowed 32% from FY 2023). Products in clinical trials Phase I: 1Board Change • Oct 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Mar 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 05Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023, at 15:00 AUS Eastern Standard Time.Board Change • Sep 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Earnings have declined by 13% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.2m). Market cap is less than US$100m (AU$21.3m market cap, or US$13.6m).Board Change • Aug 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Mar 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 06No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Dec 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vectus Biosystems は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:VBS - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-1-1-1N/A9/30/20250-2-1-1N/A6/30/20250-2-1-1N/A3/31/20251-2-1-1N/A12/31/20241-2-1-1N/A9/30/20241-2-2-2N/A6/30/20241-2-2-2N/A3/31/20241-2-2-2N/A12/31/20231-2-1-1N/A9/30/20231-3-2-2N/A6/30/20231-3-2-2N/A3/31/20232-4-3-3N/A12/31/20222-4-4-4N/A9/30/20222-4-4-4N/A6/30/20221-4-4-4N/A3/31/20221-4-4-4N/A12/31/20211-4-4-4N/A9/30/20211-4-4-4N/A6/30/20211-4-3-3N/A3/31/20211-4-3-3N/A12/31/20200-4-2-2N/A9/30/20200-4-3-3N/A6/30/20200-3-3-3N/A3/31/20200-3-3-3N/A12/31/20190-2-2-2N/A9/30/20190-2N/A-2N/A6/30/20190-2N/A-1N/A3/31/20190-2N/A-2N/A12/31/20180-2N/A-2N/A9/30/20180-2N/A-2N/A6/30/20180-3N/A-1N/A3/31/20180-3N/A-1N/A12/31/20170-3N/A-1N/A9/30/20170-3N/A-3N/A6/30/20170-4N/A-4N/A3/31/20170-4N/A-4N/A12/31/20160-4N/A-4N/A9/30/20160-4N/A-3N/A6/30/20160-3N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VBSの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VBSの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VBSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VBSの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VBSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VBSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 15:34終値2026/07/09 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vectus Biosystems Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 27Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million.Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million. Security Name: Odinary Shares Security Type: Common Stock Securities Offered: 7,910,000 Price\Range: AUD 0.1 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • May 22Vectus Biosystems Limited has filed a Follow-on Equity Offering.Vectus Biosystems Limited has filed a Follow-on Equity Offering. Security Name: Odinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • Oct 09Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.033 loss per share (vs AU$0.044 loss in FY 2024)Full year 2025 results: AU$0.033 loss per share (improved from AU$0.044 loss in FY 2024). Revenue: AU$478.2k (down 58% from FY 2024). Net loss: AU$1.78m (loss narrowed 24% from FY 2024).
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 20Vectus Biosystems Limited Appoints Linda Ann Walters as Non-Executive Director of the BoardVectus Biosystems Limited announced the appointment of Linda Ann Walters as a non-executive director of the board of the company, effective from 20 December 2024. Linda Walters has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. Linda has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization programme. Her expertise spans the fields of human resources, finance, information technology and the commercialization of IP. Linda has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus' operational and commercial capabilities.
お知らせ • Oct 08Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024.
Reported Earnings • Oct 05Full year 2024 earnings released: AU$0.044 loss per share (vs AU$0.072 loss in FY 2023)Full year 2024 results: AU$0.044 loss per share (improved from AU$0.072 loss in FY 2023). Revenue: AU$1.14m (down 16% from FY 2023). Net loss: AU$2.34m (loss narrowed 32% from FY 2023). Products in clinical trials Phase I: 1
Board Change • Oct 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 23No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Mar 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 05Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023, at 15:00 AUS Eastern Standard Time.
Board Change • Sep 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Earnings have declined by 13% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.2m). Market cap is less than US$100m (AU$21.3m market cap, or US$13.6m).
Board Change • Aug 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Mar 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 06No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Dec 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.